PharmaCyte Biotech Inc. (PMCB): Price and Financial Metrics
GET POWR RATINGS... FREE!
PMCB Stock Price Chart Interactive Chart >
PMCB Price/Volume Stats
| Current price | $2.23 | 52-week high | $21.45 |
| Prev. close | $2.19 | 52-week low | $1.79 |
| Day low | $2.19 | Volume | 44,000 |
| Day high | $2.26 | Avg. volume | 335,374 |
| 50-day MA | $2.23 | Dividend yield | N/A |
| 200-day MA | $2.62 | Market Cap | 46.21M |
PharmaCyte Biotech Inc. (PMCB) Company Bio
PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
Latest PMCB News From Around the Web
Below are the latest news stories about PharmaCyte Biotech Inc that investors may wish to consider to help them evaluate PMCB as an investment opportunity.
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of IntegrationLAS VEGAS, February 22, 2022--PharmaCyte announces genetic stability of the cytochrome P450 gene and site of integration for its pancreatic cancer product candidate. |
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDALAS VEGAS, February 14, 2022--PharmaCyte Biotech updates status of its Investigational New Drug Application to the FDA. |
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect ConferenceLAS VEGAS, January 06, 2022--PharmaCyte Biotech Chief Executive Officer to present at the H.C. Wainwright BioConnect Conference. |
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated CellsLAS VEGAS, January 04, 2022--PharmaCyte Biotech biocompatibility study proves that its capsule material is not toxic for the encapsulated cells inside the capsules. |
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability StudyLAS VEGAS, December 28, 2021--PharmaCyte has successfully completed a 36 month stability study on its Master Cell Bank cells that will be used for treatment of pancreatic cancer. |
PMCB Price Returns
| 1-mo | -4.29% |
| 3-mo | 4.69% |
| 6-mo | -13.90% |
| 1-year | -88.29% |
| 3-year | -96.15% |
| 5-year | -97.90% |
| YTD | -10.80% |
| 2021 | -75.12% |
| 2020 | -83.46% |
| 2019 | 9.46% |
| 2018 | -33.69% |
| 2017 | -62.53% |
Loading social stream, please wait...